Format

Send to

Choose Destination
J Clin Apher. 2016 Jun;31(3):149-62. doi: 10.1002/jca.21470.

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.

Author information

1
Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York.
2
Blood Center of Wisconsin, Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin.
3
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
4
Division of Nephrology, University of Virginia, Charlottesville, Virginia.
5
Department of Medicine, Seattle Cancer Care Alliance and University of Washington, Seattle, Washington.
6
Bloodworks Northwest, Department of Laboratory Medicine, University of Washington, Seattle, Washington.
7
Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
8
Department for Pediatrics, St. Anna Kinderspital, Medical University of Vienna, Vienna, Austria.
9
Bloodworks Northwest, Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut.
10
New York Blood Center, Department of Pathology.
11
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.

Abstract

The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence-based use of therapeutic apheresis in human disease. Since the 2007 JCA Special Issue (Fourth Edition), the Committee has incorporated systematic review and evidence-based approaches in the grading and categorization of apheresis indications. This Seventh Edition of the JCA Special Issue continues to maintain this methodology and rigor to make recommendations on the use of apheresis in a wide variety of diseases/conditions. The JCA Seventh Edition, like its predecessor, has consistently applied the category and grading system definitions in the fact sheets. The general layout and concept of a fact sheet that was used since the fourth edition has largely been maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. The Seventh Edition discusses 87 fact sheets (14 new fact sheets since the Sixth Edition) for therapeutic apheresis diseases and medical conditions, with 179 indications, which are separately graded and categorized within the listed fact sheets. Several diseases that are Category IV which have been described in detail in previous editions and do not have significant new evidence since the last publication are summarized in a separate table. The Seventh Edition of the JCA Special Issue serves as a key resource that guides the utilization of therapeutic apheresis in the treatment of human disease. J. Clin. Apheresis 31:149-162, 2016.

KEYWORDS:

B2 microglobulin column; LDL apheresis; adsorptive cytapheresis; apheresis; erythrocytapheresis; extracorporeal photopheresis; filtration-based selective apheresis; highvolume plasma exchange; immunoadsorption; indications evidence based; leukocytapheresis; photopheresis; plasma exchange; platelet pheresis; red blood cell exchange; rheopheresis; therapeutic plasma exchange; thrombocytapheresis

PMID:
27322218
DOI:
10.1002/jca.21470
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center